Clinical Edge Journal Scan

Body composition reveals more details on colon cancer outcomes


 

Key clinical point: Low skeletal muscle area (SMA) and high visceral to total fat ratio were associated with worse outcomes in patients with nonmetastatic colon cancer who presented for elective resection.

Major finding: The risk for 5-year cancer recurrence after surgery was significantly higher in patients with low SMA (hazard ratio [HR], 2.30; P = .04) and high visceral to total fat ratio (HR, 5.78; P = .02). Even the risk of developing a 30-day infective complication was significantly higher in patients with low SMA (odds ratio [OR], 2.13; P = .004) and high visceral to total fat ratio (OR, 3.20; P = .01).

Study details: Findings are from a translational cohort study including 28 patients with nonmetastatic colon cancer presenting for elective resection. Included patients had no underlying chronic inflammatory disorders and were not receiving anti-inflammatory drugs.

Disclosures: This study received no funding. No conflict of interests was reported.

Source: Fleming CA et al. JAMA Netw Open. 2021 Aug 30. doi:10.1001/jamanetworkopen.2021.15274.

Recommended Reading

Obesity tied to increased risk for colorectal cancer in patients with Lynch syndrome
MDedge Hematology and Oncology
Dietary vitamin D intake tied to lower risk for colorectal cancer in patients at high CV risk
MDedge Hematology and Oncology
FTD/TPI effective and well tolerated in elderly patients with advanced colorectal cancer
MDedge Hematology and Oncology
Diagnostic efficacy of fecal immunochemical tests for assessment of suspected symptomatic CRC in primary care
MDedge Hematology and Oncology
Avoiding intensive chemotherapy due to older age alone is not advisable in mCRC
MDedge Hematology and Oncology
AGA Clinical Practice Update Expert Review: Management of malignant alimentary tract obstruction
MDedge Hematology and Oncology
Shorter HCC screening intervals benefit high-risk patients
MDedge Hematology and Oncology
Colorectal polyps often recur after incomplete resection
MDedge Hematology and Oncology
Metastatic CRC: Repeated anti-EGFR therapy shows promise in phase 2
MDedge Hematology and Oncology
Metastatic CRC: Better tumor response and disease control with FTD/TPI vs regorafenib
MDedge Hematology and Oncology